According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.37594. At the end of 2023 the company had a P/S ratio of 4.08.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.08 | 26.93% |
2022 | 3.21 | -20.32% |
2021 | 4.03 | -36.08% |
2020 | 6.31 | 13.98% |
2019 | 5.53 | -19.92% |
2018 | 6.91 | -65.24% |
2017 | 19.9 | -11.96% |
2016 | 22.6 | -34.72% |
2015 | 34.6 | 207.89% |
2014 | 11.2 | -68.88% |
2013 | 36.1 | 104.02% |
2012 | 17.7 | 698.31% |
2011 | 2.22 | -54.29% |
2010 | 4.85 | -7.48% |
2009 | 5.24 | 16.52% |
2008 | 4.50 | -43.54% |
2007 | 7.97 | -9.01% |
2006 | 8.76 | -15.35% |
2005 | 10.3 | -23.26% |
2004 | 13.5 | 38.21% |
2003 | 9.75 | -9.02% |
2002 | 10.7 | -52.9% |
2001 | 22.8 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.10 | 21.39% | ๐บ๐ธ USA |
Pfizer PFE | 2.80 | -17.13% | ๐บ๐ธ USA |
Amgen AMGN | 6.07 | 79.83% | ๐บ๐ธ USA |
Sanofi SNY | 2.49 | -26.22% | ๐ซ๐ท France |
Merck MRK | 5.58 | 65.21% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 2.00 | -40.79% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.43 | -28.14% | ๐ฌ๐ง UK |
Curis CRIS | 7.64 | 126.45% | ๐บ๐ธ USA |
AVEO Oncology
AVEO | 5.53 | 63.76% | ๐บ๐ธ USA |